Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimi Health Corp (OPTI) has signed a supply agreement with Filament Health (FH), a clinical-stage natural psychedelic drug development company
  • Optimi has been engaged by Filament to supply psilocybin mushrooms
  • The two companies believe that the agreement sends a strong message that safety and research are paramount to growing a safe and secure supply of natural psilocybin
  • Optimi Health Corp. is a homegrown company producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms
  • Filament Health is a clinical-stage natural psychedelic drug development company
  • Optimi Health Corp. opened trading at C$0.35

Optimi Health Corp (OPTI) has signed a supply agreement with Filament Health, a clinical-stage natural psychedelic drug development company.

Filament has engaged Optimi to supply psilocybin mushrooms cultivated in Optimi’s recently inaugurated 20,000 square foot EU-GMP Princeton, British Columbia, facility to produce whole, dried mushroom fruiting bodies for potential drug development and analysis by Filament’s research team.

“Our supply agreement with Filament Health is an excellent fit for both parties,” stated Optimi CEO Bill Ciprick.

“Filament’s commitment to developing unique intellectual properties using natural psychedelic medicines and the advancement of natural psilocybin in the space as a whole is well-aligned with our values and goals for the future of psychedelics,” he added.

“We are pleased to partner with Optimi as we build out our own supply chain and explore external suppliers,” noted Filament Health CEO and Co-Founder Benjamin Lightburn.

“This is an important step for Filament, and we look forward to determining the compatibility of Optimi’s product with our industry-leading natural extraction technology,” he added.

The two companies believe that the agreement sends a strong message that safety and research are paramount to growing a safe and secure supply of natural psilocybin.

Optimi Health Corp. is a homegrown company producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Filament Health is a clinical-stage natural psychedelic drug development company.

Optimi Health Corp. (OPTI) opened trading at $0.35.

More From The Market Herald
MindBio Therapeutics - Chief Executive, Justin Hanka.

" Psychedelics stock moving forward with pioneering LSD clinical trial

Psychedelics stock MindBio Therapeutics receives ethics approval for its Phase 2a take-home LSD microdosing clinical trial.

" Clearmind (CSE:CMND) approved to conduct clinical trial on alcohol use disorder

Clearmind (CMND) received approval for its CMND-100 compound to treat alcohol use disorder at Israel’s IMCA center.

" Optimi Health (CSE:OPTI) granted a Natural Health Product Site Licence by Health Canada

Optimi Health (OPTI) has received a Natural Health Product Site Licence by Health Canada.
The Market Herald Video

" Psyched Wellness (CSE:PSYC) and HealingMaps to offer Amanita Muscaria tincture, Calm, to HealingMaps universe

This is sponsored content issued on behalf of Psyched Wellness, please see full disclaimer here.